Argus positive on Sanofi’s diverse range of businesses

Argus analyst Jasper Hellweg keeps a Buy rating and $55 price target on Sanofi while noting that the firm is positive on the company’s “diverse” range of businesses, which include branded pharmaceuticals, generics, vaccines, and consumer healthcare products. The company has seen “particularly strong” sales of Dupixent, a treatment for asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyposis, chronic spontaneous urticarial, eosinophilic esophagitis, and prurigo nodularis, which is also being studied for other indications, the analyst tells investors in a research note, adding that if approved, Dupixent would be the first-ever targeted therapy for COPD in the EU and the first new treatment approach for this disease in more than a decade.